Study on Colloidal Radioactive Chromic Phosphate for Malignant Effusions
Author Information
Author(s): H. A. S. Van Den Brenk, K. H. Clarke, W. P. Holman, Carmyl Winkler
Primary Institution: Peter MacCallum Clinic, Melbourne, Australia
Hypothesis
The study aims to assess the safety and efficacy of colloidal radioactive chromic phosphate (Cr32PO4) in treating malignant effusions.
Conclusion
The use of radioactive colloidal chromic phosphate is recommended for treating malignant serous effusions due to its low hazard to patients and staff.
Supporting Evidence
- 8 out of 16 patients showed marked clinical improvement after treatment.
- The study indicates that Cr32PO4 can deliver similar radiation effects as higher doses of colloidal gold.
- Dialysis of Cr32PO4 before administration reduces the amount of ionic radioactive phosphate.
Takeaway
Doctors tested a special radioactive liquid to help patients with fluid buildup from cancer, and it seemed to work well without hurting anyone.
Methodology
Patients received varying doses of Cr32PO4, and their clinical progress was monitored along with laboratory tests for radioactive assays.
Limitations
The study provides only preliminary results and lacks a controlled comparison group.
Participant Demographics
The study included 16 patients with malignant serous effusions, comprising both pleural and peritoneal effusions.
Want to read the original?
Access the complete publication on the publisher's website